<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">35022247</PMID><DateCompleted><Year>2022</Year><Month>03</Month><Day>22</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>22</Day></DateRevised><Article PubModel="Electronic-Print"><Journal><ISSN IssnType="Electronic">2575-1077</ISSN><JournalIssue CitedMedium="Internet"><Volume>5</Volume><Issue>4</Issue><PubDate><Year>2022</Year><Month>Apr</Month></PubDate></JournalIssue><Title>Life science alliance</Title><ISOAbbreviation>Life Sci Alliance</ISOAbbreviation></Journal><ArticleTitle>Testing of the therapeutic efficacy and safety of AMPA receptor RNA aptamers in an ALS mouse model.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">e202101193</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.26508/lsa.202101193</ELocationID><Abstract><AbstractText>In motor neurons of sporadic amyotrophic lateral sclerosis (ALS) patients, the RNA editing at the glutamine/arginine site of the GluA2 subunit of &#x3b1;-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid (AMPA) receptors is defective or incomplete. As a result, AMPA receptors containing the abnormally expressed, unedited isoform of GluA2 are highly Ca<sup>2+</sup>-permeable, and are responsible for mediating abnormal Ca<sup>2+</sup> influx, thereby triggering motor neuron degeneration and cell death. Thus, blocking the AMPA receptor-mediated, abnormal Ca<sup>2+</sup> influx is a potential therapeutic strategy for treatment of sporadic ALS. Here, we report a study of the efficacy and safety of two RNA aptamers targeting AMPA receptors on the ALS phenotype of AR2 mice. A 12-wk continuous, intracerebroventricular infusion of aptamers to AR2 mice reduced the progression of motor dysfunction, normalized TDP-43 mislocalization, and prevented death of motor neurons. Our results demonstrate that the use of AMPA receptor aptamers as a novel class of AMPA receptor antagonists is a promising strategy for developing an ALS treatment approach.</AbstractText><CopyrightInformation>&#xa9; 2022 Akamatsu et al.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Akamatsu</LastName><ForeName>Megumi</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-6893-805X</Identifier><AffiliationInfo><Affiliation>Department of Neurology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yamashita</LastName><ForeName>Takenari</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Neurology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Teramoto</LastName><ForeName>Sayaka</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Neurology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Tokyo Medical University, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Huang</LastName><ForeName>Zhen</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Department of Chemistry, University of Albany, State University of New York, Albany, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lynch</LastName><ForeName>Janet</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Chemistry, University of Albany, State University of New York, Albany, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Toda</LastName><ForeName>Tatsushi</ForeName><Initials>T</Initials><Identifier Source="ORCID">0000-0002-0717-1123</Identifier><AffiliationInfo><Affiliation>Department of Neurology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Niu</LastName><ForeName>Li</ForeName><Initials>L</Initials><Identifier Source="ORCID">0000-0002-0917-9663</Identifier><AffiliationInfo><Affiliation>Department of Chemistry, University of Albany, State University of New York, Albany, NY, USA lniu@albany.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kwak</LastName><ForeName>Shin</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0002-9936-6664</Identifier><AffiliationInfo><Affiliation>Department of Neurology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan kwak@tokyo-med.ac.jp.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Tokyo Medical University, Tokyo, Japan.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R21 NS106392</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>01</Month><Day>12</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Life Sci Alliance</MedlineTA><NlmUniqueID>101728869</NlmUniqueID><ISSNLinking>2575-1077</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D052157">Aptamers, Nucleotide</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018091">Receptors, AMPA</NameOfSubstance></Chemical></ChemicalList><SupplMeshList><SupplMeshName Type="Disease" UI="C531617">Amyotrophic lateral sclerosis 1</SupplMeshName></SupplMeshList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D052157" MajorTopicYN="N">Aptamers, Nucleotide</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016503" MajorTopicYN="N">Drug Delivery Systems</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009046" MajorTopicYN="N">Motor Neurons</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017393" MajorTopicYN="N">RNA Editing</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018091" MajorTopicYN="Y">Receptors, AMPA</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>The authors declare that they have no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>8</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2021</Year><Month>12</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>12</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>1</Month><Day>13</Day><Hour>5</Hour><Minute>56</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>1</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>3</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35022247</ArticleId><ArticleId IdType="pmc">PMC8761490</ArticleId><ArticleId IdType="doi">10.26508/lsa.202101193</ArticleId><ArticleId IdType="pii">5/4/e202101193</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Aizawa H, Hideyama T, Yamashita T, Kimura T, Suzuki N, Aoki M, Kwak S (2016) Deficient RNA-editing enzyme ADAR2 in an amyotrophic lateral sclerosis patient with a FUS(P525L) mutation. J Clin Neurosci 32: 128&#x2013;129. 10.1016/j.jocn.2015.12.039</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jocn.2015.12.039</ArticleId><ArticleId IdType="pubmed">27343041</ArticleId></ArticleIdList></Reference><Reference><Citation>Aizawa H, Sawada J, Hideyama T, Yamashita T, Katayama T, Hasebe N, Kimura T, Yahara O, Kwak S (2010) TDP-43 pathology in sporadic ALS occurs in motor neurons lacking the RNA editing enzyme ADAR2. Acta Neuropathol 120: 75&#x2013;84. 10.1007/s00401-010-0678-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-010-0678-x</ArticleId><ArticleId IdType="pubmed">20372915</ArticleId></ArticleIdList></Reference><Reference><Citation>Akamatsu M, Yamashita T, Hirose N, Teramoto S, Kwak S (2016) The AMPA receptor antagonist perampanel robustly rescues amyotrophic lateral sclerosis (ALS) pathology in sporadic ALS model mice. Sci Rep 6: 28649. 10.1038/srep28649</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/srep28649</ArticleId><ArticleId IdType="pmc">PMC4923865</ArticleId><ArticleId IdType="pubmed">27350567</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Chalabi A, Hardiman O (2013) The epidemiology of ALS: A conspiracy of genes, environment and time. Nat Rev Neurol 9: 617&#x2013;628. 10.1038/nrneurol.2013.203</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrneurol.2013.203</ArticleId><ArticleId IdType="pubmed">24126629</ArticleId></ArticleIdList></Reference><Reference><Citation>Anraku Y, Kuwahara H, Fukusato Y, Mizoguchi A, Ishii T, Nitta K, Matsumoto Y, Toh K, Miyata K, Uchida S, et al. (2017) Glycaemic control boosts glucosylated nanocarrier crossing the BBB into the brain. Nat Commun 8: 1001. 10.1038/s41467-017-00952-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-017-00952-3</ArticleId><ArticleId IdType="pmc">PMC5645389</ArticleId><ArticleId IdType="pubmed">29042554</ArticleId></ArticleIdList></Reference><Reference><Citation>Arai T, Hasegawa M, Akiyama H, Ikeda K, Nonaka T, Mori H, Mann D, Tsuchiya K, Yoshida M, Hashizume Y, et al. (2006) TDP-43 is a component of ubiquitin-positive tau-negative inclusions in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Biochem Biophys Res Commun 351: 602&#x2013;611. 10.1016/j.bbrc.2006.10.093</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbrc.2006.10.093</ArticleId><ArticleId IdType="pubmed">17084815</ArticleId></ArticleIdList></Reference><Reference><Citation>Brody EN, Gold L (2000) Aptamers as therapeutic and diagnostic agents. J Biotechnol 74: 5&#x2013;13. 10.1016/s1389-0352(99)00004-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s1389-0352(99)00004-5</ArticleId><ArticleId IdType="pubmed">10943568</ArticleId></ArticleIdList></Reference><Reference><Citation>Ellington AD, Szostak JW (1990) In vitro selection of RNA molecules that bind specific ligands. Nature 346: 818&#x2013;822. 10.1038/346818a0</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/346818a0</ArticleId><ArticleId IdType="pubmed">1697402</ArticleId></ArticleIdList></Reference><Reference><Citation>Fukushima K, Hatanaka K, Sagane K, Ido K (2020) Inhibitory effect of anti-seizure medications on ionotropic glutamate receptors: Special focus on AMPA receptor subunits. Epilepsy Res 167: 106452. 10.1016/j.eplepsyres.2020.106452</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.eplepsyres.2020.106452</ArticleId><ArticleId IdType="pubmed">32911258</ArticleId></ArticleIdList></Reference><Reference><Citation>Gerber A, O&#x2019;Connell MA, Keller W (1997) Two forms of human double-stranded RNA-specific editase 1 (hRED1) generated by the insertion of an Alu cassette. RNA 3: 453&#x2013;463.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1369496</ArticleId><ArticleId IdType="pubmed">9149227</ArticleId></ArticleIdList></Reference><Reference><Citation>Grasso S, Micale N, Zappal&#xe0; M, Galli A, Costagli C, Menniti FS, De Micheli C (2003) Characterization of the mechanism of anticonvulsant activity for a selected set of putative AMPA receptor antagonists. Bioorg Med Chem Lett 13: 443&#x2013;446. 10.1016/s0960-894x(02)00955-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0960-894x(02)00955-1</ArticleId><ArticleId IdType="pubmed">12565947</ArticleId></ArticleIdList></Reference><Reference><Citation>Greenwood J, Valdes J (2016) Perampanel (Fycompa): A review of clinical efficacy and safety in epilepsy. P T 41: 683&#x2013;698.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5083075</ArticleId><ArticleId IdType="pubmed">27904300</ArticleId></ArticleIdList></Reference><Reference><Citation>Hanada T, Hashizume Y, Tokuhara N, Takenaka O, Kohmura N, Ogasawara A, Hatakeyama S, Ohgoh M, Ueno M, Nishizawa Y (2011) Perampanel: A novel, orally active, noncompetitive AMPA-receptor antagonist that reduces seizure activity in rodent models of epilepsy. Epilepsia 52: 1331&#x2013;1340. 10.1111/j.1528-1167.2011.03109.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1528-1167.2011.03109.x</ArticleId><ArticleId IdType="pubmed">21635236</ArticleId></ArticleIdList></Reference><Reference><Citation>Hideyama T, Kwak S (2011) When does ALS start? ADAR2-GluA2 hypothesis for the etiology of sporadic ALS. Front Mol Neurosci 4: 33. 10.3389/fnmol.2011.00033</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnmol.2011.00033</ArticleId><ArticleId IdType="pmc">PMC3214764</ArticleId><ArticleId IdType="pubmed">22102833</ArticleId></ArticleIdList></Reference><Reference><Citation>Hideyama T, Yamashita T, Aizawa H, Tsuji S, Kakita A, Takahashi H, Kwak S (2012) Profound downregulation of the RNA editing enzyme ADAR2 in ALS spinal motor neurons. Neurobiol Dis 45: 1121&#x2013;1128. 10.1016/j.nbd.2011.12.033</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbd.2011.12.033</ArticleId><ArticleId IdType="pubmed">22226999</ArticleId></ArticleIdList></Reference><Reference><Citation>Hideyama T, Yamashita T, Suzuki T, Tsuji S, Higuchi M, Seeburg PH, Takahashi R, Misawa H, Kwak S (2010) Induced loss of ADAR2 engenders slow death of motor neurons from Q/R site-unedited GluR2. J Neurosci 30: 11917&#x2013;11925. 10.1523/JNEUROSCI.2021-10.2010</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.2021-10.2010</ArticleId><ArticleId IdType="pmc">PMC6633551</ArticleId><ArticleId IdType="pubmed">20826656</ArticleId></ArticleIdList></Reference><Reference><Citation>Higuchi M, Maas S, Single FN, Hartner J, Rozov A, Burnashev N, Feldmeyer D, Sprengel R, Seeburg PH (2000) Point mutation in an AMPA receptor gene rescues lethality in mice deficient in the RNA-editing enzyme ADAR2. Nature 406: 78&#x2013;81. 10.1038/35017558</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/35017558</ArticleId><ArticleId IdType="pubmed">10894545</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang Z, Han Y, Wang C, Niu L (2010) Potent and selective inhibition of the open-channel conformation of AMPA receptors by an RNA aptamer. Biochemistry 49: 5790&#x2013;5798. 10.1021/bi100690k</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/bi100690k</ArticleId><ArticleId IdType="pmc">PMC2908592</ArticleId><ArticleId IdType="pubmed">20518485</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang Z, Jayaseelan S, Hebert J, Seo H, Niu L (2013) Single-nucleotide resolution of RNAs up to 59 nucleotides by high-performance liquid chromatography. Anal Biochem 435: 35&#x2013;43. 10.1016/j.ab.2012.12.011</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ab.2012.12.011</ArticleId><ArticleId IdType="pmc">PMC5577504</ArticleId><ArticleId IdType="pubmed">23274387</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang Z, Pei W, Jayaseelan S, Shi H, Niu L (2007) RNA aptamers selected against the GluR2 glutamate receptor channel. Biochemistry 46: 12648&#x2013;12655. 10.1021/bi701036p</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/bi701036p</ArticleId><ArticleId IdType="pubmed">17929944</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang Z, Wen W, Wu A, Niu L (2017) Chemically modified, &#x3b1;-amino-3-hydroxy-5-methyl-4-isoxazole (AMPA) receptor RNA aptamers designed for in vivo use. ACS Chem Neurosci 8: 2437&#x2013;2445. 10.1021/acschemneuro.7b00211</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acschemneuro.7b00211</ArticleId><ArticleId IdType="pubmed">28872832</ArticleId></ArticleIdList></Reference><Reference><Citation>Kanazawa I (2001) How do neurons die in neurodegenerative diseases? Trends Mol Med 7: 339&#x2013;344. 10.1016/s1471-4914(01)02017-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s1471-4914(01)02017-2</ArticleId><ArticleId IdType="pubmed">11516993</ArticleId></ArticleIdList></Reference><Reference><Citation>Kawahara Y, Ito K, Sun H, Aizawa H, Kanazawa I, Kwak S (2004) Glutamate receptors: RNA editing and death of motor neurons. Nature 427: 801. 10.1038/427801a</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/427801a</ArticleId><ArticleId IdType="pubmed">14985749</ArticleId></ArticleIdList></Reference><Reference><Citation>Kawahara Y, Ito K, Sun H, Kanazawa I, Kwak S (2003) Low editing efficiency of GluR2 mRNA is associated with a low relative abundance of ADAR2 mRNA in white matter of normal human brain. Eur J Neurosci 18: 23&#x2013;33. 10.1046/j.1460-9568.2003.02718.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.1460-9568.2003.02718.x</ArticleId><ArticleId IdType="pubmed">12859334</ArticleId></ArticleIdList></Reference><Reference><Citation>Kawahara Y, Kwak S (2005) Excitotoxicity and ALS: What is unique about the AMPA receptors expressed on spinal motor neurons? Amyotroph Lateral Scler Other Motor Neuron Disord 6: 131&#x2013;144. 10.1080/14660820510037872</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/14660820510037872</ArticleId><ArticleId IdType="pubmed">16183555</ArticleId></ArticleIdList></Reference><Reference><Citation>Kiernan JA, Hudson AJ (1993) Changes in shapes of surviving motor neurons in amyotrophic lateral sclerosis. Brain 116: 203&#x2013;215. 10.1093/brain/116.1.203</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/116.1.203</ArticleId><ArticleId IdType="pubmed">8453457</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim G, Gautier O, Tassoni-Tsuchida E, Ma XR, Gitler AD (2020) ALS genetics: Gains, losses, and implications for future therapies. Neuron 108: 822&#x2013;842. 10.1016/j.neuron.2020.08.022</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2020.08.022</ArticleId><ArticleId IdType="pmc">PMC7736125</ArticleId><ArticleId IdType="pubmed">32931756</ArticleId></ArticleIdList></Reference><Reference><Citation>Kwak S, Kawahara Y (2005) Deficient RNA editing of GluR2 and neuronal death in amyotropic lateral sclerosis. J Mol Med (Berl) 83: 110&#x2013;120. 10.1007/s00109-004-0599-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00109-004-0599-z</ArticleId><ArticleId IdType="pubmed">15624111</ArticleId></ArticleIdList></Reference><Reference><Citation>Li G, Niu L (2004) How fast does the GluR1Qflip channel open? J Biol Chem 279: 3990&#x2013;3997. 10.1074/jbc.M310410200</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M310410200</ArticleId><ArticleId IdType="pubmed">14610080</ArticleId></ArticleIdList></Reference><Reference><Citation>Melcher T, Maas S, Herb A, Sprengel R, Seeburg PH, Higuchi M (1996) A mammalian RNA editing enzyme. Nature 379: 460&#x2013;464. 10.1038/379460a0</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/379460a0</ArticleId><ArticleId IdType="pubmed">8559253</ArticleId></ArticleIdList></Reference><Reference><Citation>Misawa H, Nakata K, Toda K, Matsuura J, Oda Y, Inoue H, Tateno M, Takahashi R (2003) VAChT-Cre. Fast and VAChT-Cre.Slow: Postnatal expression of Cre recombinase in somatomotor neurons with different onset. Genesis 37: 44&#x2013;50. 10.1002/gene.10224</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/gene.10224</ArticleId><ArticleId IdType="pubmed">14502577</ArticleId></ArticleIdList></Reference><Reference><Citation>Moore S, Alsop E, Lorenzini I, Starr A, Rabichow BE, Mendez E, Levy JL, Burciu C, Reiman R, Chew J, et al. (2019) ADAR2 mislocalization and widespread RNA editing aberrations in C9orf72-mediated ALS/FTD. Acta Neuropathol 138: 49&#x2013;65. 10.1007/s00401-019-01999-w</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-019-01999-w</ArticleId><ArticleId IdType="pmc">PMC6750285</ArticleId><ArticleId IdType="pubmed">30945056</ArticleId></ArticleIdList></Reference><Reference><Citation>Neumann M, Sampathu DM, Kwong LK, Truax AC, Micsenyi MC, Chou TT, Bruce J, Schuck T, Grossman M, Clark CM, et al. (2006) Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science 314: 130&#x2013;133. 10.1126/science.1134108</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1134108</ArticleId><ArticleId IdType="pubmed">17023659</ArticleId></ArticleIdList></Reference><Reference><Citation>Paez-Colasante X, Figueroa-Romero C, Sakowski SA, Goutman SA, Feldman EL (2015) Amyotrophic lateral sclerosis: Mechanisms and therapeutics in the epigenomic era. Nat Rev Neurol 11: 266&#x2013;279. 10.1038/nrneurol.2015.57</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrneurol.2015.57</ArticleId><ArticleId IdType="pubmed">25896087</ArticleId></ArticleIdList></Reference><Reference><Citation>Pieken WA, Olsen DB, Benseler F, Aurup H, Eckstein F (1991) Kinetic characterization of ribonuclease-resistant 2&#x2032;-modified hammerhead ribozymes. Science 253: 314&#x2013;317. 10.1126/science.1857967</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1857967</ArticleId><ArticleId IdType="pubmed">1857967</ArticleId></ArticleIdList></Reference><Reference><Citation>Saraiva C, Pra&#xe7;a C, Ferreira R, Santos T, Ferreira L, Bernardino L (2016) Nanoparticle-mediated brain drug delivery: Overcoming blood-brain barrier to treat neurodegenerative diseases. J Control Release 235: 34&#x2013;47. 10.1016/j.jconrel.2016.05.044</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jconrel.2016.05.044</ArticleId><ArticleId IdType="pubmed">27208862</ArticleId></ArticleIdList></Reference><Reference><Citation>Sawadogo M, Roeder RG (1985) Factors involved in specific transcription by human RNA polymerase II: Analysis by a rapid and quantitative in vitro assay. Proc Natl Acad Sci U S A 82: 4394&#x2013;4398. 10.1073/pnas.82.13.4394</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.82.13.4394</ArticleId><ArticleId IdType="pmc">PMC390420</ArticleId><ArticleId IdType="pubmed">3925456</ArticleId></ArticleIdList></Reference><Reference><Citation>Seeburg PH (2002) A-to-I editing: New and old sites, functions and speculations. Neuron 35: 17&#x2013;20. 10.1016/s0896-6273(02)00760-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0896-6273(02)00760-2</ArticleId><ArticleId IdType="pubmed">12123604</ArticleId></ArticleIdList></Reference><Reference><Citation>S&#xf3;lyom S, Tarnawa I (2002) Non-competitive AMPA antagonists of 2,3-benzodiazepine type. Current Pharm Des 8: 913&#x2013;939. 10.2174/1381612024607081</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/1381612024607081</ArticleId><ArticleId IdType="pubmed">11945139</ArticleId></ArticleIdList></Reference><Reference><Citation>Sreedharan J, Blair IP, Tripathi VB, Hu X, Vance C, Rogelj B, Ackerley S, Durnall JC, Williams KL, Buratti E, et al. (2008) TDP-43 mutations in familial and sporadic amyotrophic lateral sclerosis. Science 319: 1668&#x2013;1672. 10.1126/science.1154584</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1154584</ArticleId><ArticleId IdType="pmc">PMC7116650</ArticleId><ArticleId IdType="pubmed">18309045</ArticleId></ArticleIdList></Reference><Reference><Citation>Suk TR, Rousseaux MWC (2020) The role of TDP-43 mislocalization in amyotrophic lateral sclerosis. Mol Neurodegener 15: 45. 10.1186/s13024-020-00397-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13024-020-00397-1</ArticleId><ArticleId IdType="pmc">PMC7429473</ArticleId><ArticleId IdType="pubmed">32799899</ArticleId></ArticleIdList></Reference><Reference><Citation>Takuma H, Kwak S, Yoshizawa T, Kanazawa I (1999) Reduction of GluR2 RNA editing, a molecular change that increases calcium influx through AMPA receptors, selective in the spinal ventral gray of patients with amyotrophic lateral sclerosis. Ann Neurol 46: 806&#x2013;815. 10.1002/1531-8249(199912)46:6&lt;806::aid-ana2&gt;3.0.co;2-s</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/1531-8249(199912)46:6&lt;806::aid-ana2&gt;3.0.co;2-s</ArticleId><ArticleId IdType="pubmed">10589532</ArticleId></ArticleIdList></Reference><Reference><Citation>Tuerk C, Gold L (1990) Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase. Science 249: 505&#x2013;510. 10.1126/science.2200121</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.2200121</ArticleId><ArticleId IdType="pubmed">2200121</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamashita T, Akamatsu M, Kwak S (2017) Altered intracellular milieu of ADAR2-deficient motor neurons in amyotrophic lateral sclerosis. Genes (Basel) 8: 60. 10.3390/genes8020060</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/genes8020060</ArticleId><ArticleId IdType="pmc">PMC5333049</ArticleId><ArticleId IdType="pubmed">28208729</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamashita T, Hideyama T, Hachiga K, Teramoto S, Takano J, Iwata N, Saido TC, Kwak S (2012) A role for calpain-dependent cleavage of TDP-43 in amyotrophic lateral sclerosis pathology. Nat Commun 3: 1307. 10.1038/ncomms2303</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ncomms2303</ArticleId><ArticleId IdType="pubmed">23250437</ArticleId></ArticleIdList></Reference><Reference><Citation>Yokoseki A, Shiga A, Tan CF, Tagawa A, Kaneko H, Koyama A, Eguchi H, Tsujino A, Ikeuchi T, Kakita A, et al. (2008) TDP-43 mutation in familial amyotrophic lateral sclerosis. Ann Neurol 63: 538&#x2013;542. 10.1002/ana.21392</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.21392</ArticleId><ArticleId IdType="pubmed">18438952</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>